Skip to main
CSTL
CSTL logo

CSTL Stock Forecast & Price Target

CSTL Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Castle Biosciences Inc. has demonstrated significant growth potential, as evidenced by a 92% year-over-year increase in TissueCypher test volume and a 23% quarter-over-quarter rise in 2Q25, likely bolstered by the expansion of the sales force. The company has also improved the gross margin of its TissueCypher product, with expectations of a mature gastrointestinal sales force by the second half of 2025, which could further enhance revenue generation. Comparatively, the slower growth of the DecisionDx-Melanoma test, at only 4% year-over-year, highlights TissueCypher's increasing prominence in the company's portfolio and its potential to drive future financial performance.

Bears say

Castle Biosciences Inc. faces a challenging outlook, as the expected enterprise value (EV) to revenue multiples for its dermatology and DecisionDx-UM tests are projected to be significantly lower than those for the TissueCypher product. This suggests that the market may not fully recognize the future revenue potential of the company's main offerings, particularly DecisionDx-Melanoma. Additionally, even when applying conservative estimates, the stock still appears undervalued, indicating potential concerns regarding investor confidence or broader market dynamics.

CSTL has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Castle Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Castle Biosciences Inc (CSTL) Forecast

Analysts have given CSTL a Buy based on their latest research and market trends.

According to 6 analysts, CSTL has a Buy consensus rating as of Oct 17, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $37.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $37.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Castle Biosciences Inc (CSTL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.